| Drug Name |
Gadobenate dimeglumine |
| Drug ID |
BADD_D00983 |
| Description |
Gadobenic acid (in the form of gadobenate dimeglumine) is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents. |
| Indications and Usage |
Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues. |
| Marketing Status |
approved; investigational |
| ATC Code |
V08CA08 |
| DrugBank ID |
DB00743
|
| KEGG ID |
D04283
|
| MeSH ID |
C064572
|
| PubChem ID |
105125
|
| TTD Drug ID |
D01OIL
|
| NDC Product Code |
57876-333; 0270-5164; 0270-5264 |
| UNII |
3Q6PPC19PO
|
| Synonyms |
gadobenic acid | 3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyltridecanoic acid, gadolinium | Gd-BOPTA | gadobenic acid, dimeglumine salt | gadobenate dimeglumine | gadolinium-BOPTA-Dimeg | MultiHance | Gd(BOPTA)2 | B 19036 | B-19036 | gadolinium-benzyloxypropionyl tetraacetate |
